Literature DB >> 1887529

Investigations of the efficacy of ascorbic acid therapy in cystinuria.

H Birwé1, W Schneeberger, A Hesse.   

Abstract

We investigated ascorbic acid therapy for cystinuria in a study of seven healthy control persons and seven cystinuric patients. The study lasted 9 days. During the first period, we collected 24-h urine specimens from all subjects on 3 consecutive days. Starting on day 4, all were given 5 g ascorbic acid/day for a period of 6 days. On the last 3 days, 24-h urine specimens were again collected. Quantitative amino acid determination was performed using an HPLC method described elsewhere. During ingestion of ascorbic acid, the mean excretion of cysteine by the control group increased from 134.1 to 159 mumol/day, whereas the excretion of cystine decreased from 107.1 to 82 mumol/day. The corresponding values for the cystinuric patients increased from 352.4 to 452.1 mumol/day for cysteine and decreased from 4,131.6 to 3,663.2 mumol/day for cystine. Thus, ascorbic acid seems to have only mild reducing properties in respect to cystine.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1887529     DOI: 10.1007/bf00303750

Source DB:  PubMed          Journal:  Urol Res        ISSN: 0300-5623


  3 in total

1.  Prevention of ascorbic acid interference in the measurement of oxalic acid in urine by ion-chromatography.

Authors:  W G Robertson; D S Scurr
Journal:  Clin Chim Acta       Date:  1984-06-27       Impact factor: 3.786

2.  [Cystinuria therapy by ascorbic acid (author's transl)].

Authors:  R Asper; O Schmucki
Journal:  Urol Int       Date:  1982       Impact factor: 2.089

3.  Measurement of urinary oxalate: an enzymatic and an ion chromatographic method compared.

Authors:  A Classen; A Hesse
Journal:  J Clin Chem Clin Biochem       Date:  1987-02
  3 in total
  7 in total

Review 1.  [Evidence-based pharmacological metaphylaxis of stone disease].

Authors:  M Straub; R E Hautmann
Journal:  Urologe A       Date:  2006-11       Impact factor: 0.639

Review 2.  Advances in medical treatment of renal stones.

Authors:  A Hesse; K Klocke; A Nolde; W Vahlensieck
Journal:  Urol Res       Date:  1992

Review 3.  [Recurrence prevention of kidney stone disease].

Authors:  M Straub
Journal:  Urologe A       Date:  2011-10       Impact factor: 0.639

Review 4.  [S2k guidelines on diagnostics, therapy and metaphylaxis of urolithiasis (AWMF 043/025) : Compendium].

Authors:  T Knoll; T Bach; U Humke; A Neisius; R Stein; M Schönthaler; G Wendt-Nordahl
Journal:  Urologe A       Date:  2016-07       Impact factor: 0.639

Review 5.  Cystinuria in childhood and adolescence: recommendations for diagnosis, treatment, and follow-up.

Authors:  Thomas Knoll; Antonia Zöllner; Gunnar Wendt-Nordahl; Maurice Stephan Michel; Peter Alken
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

Review 6.  Diagnosis and metaphylaxis of stone disease. Consensus concept of the National Working Committee on Stone Disease for the upcoming German Urolithiasis Guideline.

Authors:  M Straub; W L Strohmaier; W Berg; B Beck; B Hoppe; N Laube; S Lahme; M Schmidt; A Hesse; K U Koehrmann
Journal:  World J Urol       Date:  2005-11-29       Impact factor: 4.226

Review 7.  Nephrolithiasis and Nephrocalcinosis in Childhood-Risk Factor-Related Current and Future Treatment Options.

Authors:  Alexander Weigert; Bernd Hoppe
Journal:  Front Pediatr       Date:  2018-04-12       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.